Antineoplastic Agents, Heart Failure, Congestive
Conditions
Brief summary
In this study, the investigators sought to determine whether an acoustic cardiographic assessment of heart function is equivalent to Doppler-echocardiography in patients who are treated with cardio-toxic cytostatic agents.
Detailed description
Patients receiving cardio-toxic cytostatic agents are examined by Doppler-echocardiography and acoustic cardiography before, during, and after the cytostatic treatment. Doppler-echocardiography measures ejection fraction, TDI, speckle tracking, and further parameters. Acoustic cardiography (Audicor, Inovise Medical Inc., Portland, USA) simultaneously integrates heart sounds and single-channel electrocardiography input to generate multiple parameters that correlate to established hemodynamic measures. Heart function as assessed by Doppler-echocardiography is then compared to the heart function as assessed by Audicor ECG.
Interventions
DEVICEDoppler-echocardiography and acoustic cardiography
Patients receive a Doppler-echocardiography and an acoustic cardiography
Sponsors
Inovise Medical
Luzerner Kantonsspital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with malignant disease with scheduled anthracycline and trastuzumab therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of echocardiographic parameters and changes of electromechanical activation time (EMAT)and development of third heart sound as indicators of congestive heart failure | Repeated measurements over a year |
Secondary
| Measure | Time frame |
|---|---|
| Development of clinically overt congestive heart failure | One year |
Countries
Switzerland
Outcome results
None listed